Sector News

Pfizer, Mylan say COVID-19 delays will postpone their Viatris merger

March 26, 2020
Life sciences

With the novel coronavirus pandemic continuing to hamstring operations, U.S. regulators have warned that major corporate transaction reviews could be held up.

Now, thanks to COVID-19 delays, a generics megamerger between Pfizer’s Upjohn unit and Mylan has been postponed until the back half of the year.

Pfizer and Mylan delayed the close of their generics megamerger, citing “unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review process,” Mylan said in a release Thursday.

The companies now expect the merger to close in the second half of 2020, Mylan said, with no expected changes to the terms of the deal.

“Mylan, Pfizer and Upjohn are working closely on integration planning and are making significant progress toward Day 1 readiness,” Mylan said. “Together the companies continue to progress toward a successful close.”

Also on Thursday, Mylan said it would postpone its annual meeting scheduled for late April until June 30.

The Upjohn-Mylan deal delay is the first instance of pharma pushing merger deadlines in response to the ongoing novel coronavirus pandemic.

Last week, the Federal Trade Commission (FTC) and the U.S. Department of Justice warned that drugmakers’ potential inability to provide employees and documents for review could require deadline extensions for merger reviews.

AbbVie, which is working to close its $63 billion megamerger with Allergan, said it still expects to wrap up review of the deal in May after reaching a “consent agreement” with the FTC last week to offload late-stage gastrointestinal candidate brazikumab and two pancreatic enzymes. Earlier this month, that sale won approval in the EU, where regulators required the divestiture of brazikumab alone for the merger’s approval.

In late February, Pfizer and Mylan announced their filled-out C-suite at the merged company, dubbed Viatris, including a raft of former leaders at the two companies.

Viatris will appoint current Pfizer board member W. Don Cornwell as well as eight current Mylan directors: JoEllen Lyons Dillon, Neil Dimick, Melina Higgins, Harry Korman, Rajiv Malik, Richard Mark, Mark Parrish and Pauline van der Meer Mohr. Malik currently serves as Mylan’s president and will keep that role at Viatris, Pfizer said.

Those nine will join Ian Read, Pfizer’s former CEO and executive chairman; Pfizer board member James Kilts; Mylan executive chairman Robert Coury, who will retain that position at Viatris; and Michael Goettler, who was named Viatris CEO. Read, Cromwell and Kilts will step down from their roles at Pfizer to move over the new company, which is under regulatory review with a merger close date of mid-2020, Pfizer said.

Additionally, Upjohn CFO Sanjeev Narula will move to Viatris in the same role, bringing 16 years of experience at Pfizer with him.

By Kyle Blankenship

Source: Fierce Pharma

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach